Association of genetic variations in mTOR with risk of childhood acute lymphoblastic leukemia in a Chinese population

References

• Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010;36:277–285.
   PubMed Web of Science ®Google Scholar
• Howard SC, Metzger ML, Wilimas JA, . Childhood cancer epidemiology in low-income countries. Cancer 2008;112:461–472.
   PubMed Web of Science ®Google Scholar
• Nguyen K, Devidas M, Cheng SC, . Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008;22:2142–2150.
   PubMed Web of Science ®Google Scholar
• Eden T. Aetiology of childhood leukaemia. Cancer Treat Rev 2010;36:286–297.
   PubMed Web of Science ®Google Scholar
• Vijayakrishnan J, Houlston RS. Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica 2010;95:1405–1414.
   PubMed Web of Science ®Google Scholar
• Karathanasis NV, Choumerianou DM, Kalmanti M. Gene polymorphisms in childhood ALL. Pediatr Blood Cancer 2009;52:318–323.
   PubMed Web of Science ®Google Scholar
• Yan J, Yin M, Dreyer ZE, . A meta-analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children. Pediatr Blood Cancer 2011 Apr 14. [Epub ahead of print]
   Google Scholar
• Dai L, Gast A, Horska A, . A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes. Pediatr Blood Cancer 2009;52:819–823.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9–22.
   PubMed Web of Science ®Google Scholar
• Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009;8:403–413.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009;122:3589–3594.
   PubMed Web of Science ®Google Scholar
• Carayol N, Vakana E, Sassano A, . Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 2010;107:12469–12474.
   PubMed Web of Science ®Google Scholar
• Kelly KR, Rowe JH, Padmanabhan S, . Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol 2011;6:53–61.
   PubMed Web of Science ®Google Scholar
• Crazzolara R, Cisterne A, Thien M, . Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 2009;113:3297–3306.
   PubMed Web of Science ®Google Scholar
• Slattery ML, Herrick JS, Lundgreen A, . Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis 2010;31:1604–1611.
   PubMed Web of Science ®Google Scholar
• Subspecialty Group of Hematology Diseases, The Society of Pediatrics, Chinese Medical Association; Editorial Board, Chinese Journal of Pediatrics. [Suggestion of diagnosis and treatment of acute lymphoblastic leukemia in childhood]. Zhonghua Er Ke Za Zhi 2006;44:392–395.
   PubMedGoogle Scholar
• Xue Y, Xu H, Rong L, . The MIF -173G/C polymorphism and risk of childhood acute lymphoblastic leukemia in a Chinese population. Leuk Res 2010;34:1282–1286.
   PubMed Web of Science ®Google Scholar
• Latino-Martel P, Chan DS, Druesne-Pecollo N, . Maternal alcohol consumption during pregnancy and risk of childhood leukemia: systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19:1238–1260.
   PubMed Web of Science ®Google Scholar
• MacArthur AC, McBride ML, Spinelli JJ, . Risk of childhood leukemia associated with parental smoking and alcohol consumption prior to conception and during pregnancy: the cross-Canada childhood leukemia study. Cancer Causes Control 2008;19:283–295.
   PubMed Web of Science ®Google Scholar
• Bailey HD, Milne E, de Klerk NH, . Exposure to house painting and the use of floor treatments and the risk of childhood acute lymphoblastic leukemia. Int J Cancer 2011;128:2405–2414.
   PubMed Web of Science ®Google Scholar
• Lee KM, Ward MH, Han S, . Paternal smoking, genetic polymorphisms in CYP1A1 and childhood leukemia risk. Leuk Res 2009;33:250–258.
   PubMed Web of Science ®Google Scholar
• Murakami M, Ichisaka T, Maeda M, . mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 2004;24:6710–6718.
   PubMed Web of Science ®Google Scholar
• Chiarini F, Grimaldi C, Ricci F, . Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010;70:8097–8107.
   PubMed Web of Science ®Google Scholar
• Cardoso BA, Martins LR, Santos CI, . Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling. Leukemia 2009;23:206–208.
   PubMed Web of Science ®Google Scholar
• Bertrand FE, Spengemen JD, Shelton JG, . Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support. Leukemia 2005;19:98–102.
   PubMed Web of Science ®Google Scholar
• Chiarini F, Fala F, Tazzari PL, . Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009;69:3520–3528.
   PubMed Web of Science ®Google Scholar
• Sengupta TK, Leclerc GM, Hsieh-Kinser TT, . Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 2007;6:46.
   PubMed Web of Science ®Google Scholar
• Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009;23:655–674.
   PubMed Web of Science ®Google Scholar
• van der Burg M, Poulsen TS, Hunger SP, . Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia. Leukemia 2004;18:895–908.
   PubMed Web of Science ®Google Scholar
• Hildebrandt MA, Yang H, Hung MC, . Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009;27:857–871.
   PubMed Web of Science ®Google Scholar
• Pu X, Hildebrandt MA, Lu C, . PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer 2011;71:82–88.
   PubMed Web of Science ®Google Scholar